[ad_1]
Los Angeles, USA, July 6, 2021 (Global News Agency)- Septic Shock Pipeline Insight 2021: Pipeline product overview, pipeline assessment, unmet needs
The report provides the latest information about Septic Shock pipeline products developed by well-known companies such as Adrenomed, MYND Life Sciences, Inotrem, Vivacelle Bio, Palisade Bio, etc.
DelveInsight’s “Septic tank impact pipeline insightThe report provides information on 10+ Company and 10+ Pipeline drugs in the Septic Shock pipeline landscape. It includes an overview of Septic Shock pipeline drugs, including clinical and non-clinical stage products. It also includes septic shock therapy assessments by product type, stage, route of administration, and molecular type, and highlights non-active septic shock pipeline products.
Some key points Septic tank impact pipe report
- Big companies such as Adrenomed, MYND Life Science, Inotrem, Vivacelle Bio, Palisade Bio, Baxter Healthcare Corporation, RegeneRx Biopharmaceuticals, Pharmazz, Inc., La Jolla Pharmaceutical, And others are developing potential drug candidates to improve treatment options for septic shock.
- Critical septic tank impact pipeline candidates, such as Adrelizumab, Nanjibotide, Tranexamic acid, Timbetasin, VIII-S OctaplasLG; And others are studying different stages of clinical trials to treat septic shock.
- Adrelizumab It is a first-class drug in the clinical stage that targets the loss of vascular integrity. The strong reason for Adrecizumab is the elegance of its mode of action. This monoclonal antibody binds to its target adrenomedullin to maintain its function as a vascular integrity regulator. Adrecizumab is currently under clinical evaluation. In the Phase II proof-of-concept trial of AdrenOSS-2 septic shock, compared with placebo, Adrecizumab showed good safety, well tolerated and established the survival trend of patients treated with Adrecizumab. Previous phase I trials have shown good safety and tolerability. The company is preparing to start Phase IIb/III trials in early 2022.
- April 2021, Nok Pharmaceutical Announced an international patent application to protect the use of experimental anti-cancer drugs, on the way® (idronoxil), to prevent the development of septic shock associated with COVID-19 and influenza virus infection.
- In March 2021, Modus Therapeutics AB An updated strategy was announced, acknowledging that the company is focused on clinical development Hepparin As a new and important potential for septic shock treatment and possible other serious inflammatory complications. Modus Therapeutics is expected to start the first clinical trial of this new indication with sevuparin, which has shown good safety around the end of 2021.
Get an overview of the pipeline landscape@ Clinical trial analysis of septic shock
Septic shock is defined as sepsis associated with hypotension and abnormal perfusion despite adequate fluid resuscitation. It is a complication of sepsis and can lead to severe sepsis and septic shock.
Emerging drugs for septic shock
- Adrecizumab: Adrenomed
Adrelizumab Is a proprietary humanized monoclonal adrenomedullin (ADM) specific antibody. This targeted therapy can inhibit the ADM induced by excessive circulating sepsis, stimulate the protection of the endothelial barrier, and reduce the interstitial vasodilation.
Research and development
second stage
NCT03085758: In December 2017, Adrenomed initiated a double-blind, placebo-controlled, randomized, multicenter, proof-of-concept and dose-exploring phase II clinical trial to explore the effects of ADRECIZUMAB in patients with septic shock and elevated adrenomedullin Safety, tolerability and efficacy. The trial was completed in December 2019 with a total of 301 participants. The biomarker-guided, randomized, double-blind, placebo-controlled proof-of-concept trial AdrenOSS-2 explored the safety, tolerability and effectiveness of Adrecizumab in 301 patients with early septic shock, and improved the vasoprotective peptide adrenal gland The blood level of medullasin. Belgium, France, Germany and the Netherlands. In addition to standard care, patients also take Adrecizumab or placebo.
The monoclonal antibody Adrecizumab given on the basis of standard care is well tolerated, shows good safety, and shows a positive survival trend. This study verified the mode of action of Adrecizumab: the combination of antibodies and bioactive adrenomedullin (bio-ADM) regulates the plasma levels of bio-ADM, which is an important hormone for vascular integrity and endothelial function.
- Nanjibotide: Inotrem
Nanjibotide Is a chemical synthesis…
The full story on Benzinga.com
[ad_2]
Source link
